These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
124 related articles for article (PubMed ID: 28447743)
1. Binding of circulating anti-MUC1 antibody and serum MUC1 antigen in stage IV breast cancer. Tang Y; Cui X; Xiao H; Qi S; Hu X; Yu Q; Shi G; Zhang X; Gu J; Yu Y; Wang L; Li Y Mol Med Rep; 2017 May; 15(5):2659-2664. PubMed ID: 28447743 [TBL] [Abstract][Full Text] [Related]
2. Survival in early breast cancer patients is favorably influenced by a natural humoral immune response to polymorphic epithelial mucin. von Mensdorff-Pouilly S; Verstraeten AA; Kenemans P; Snijdewint FG; Kok A; Van Kamp GJ; Paul MA; Van Diest PJ; Meijer S; Hilgers J J Clin Oncol; 2000 Feb; 18(3):574-83. PubMed ID: 10653872 [TBL] [Abstract][Full Text] [Related]
3. MUC1 serum assays in breast cancer: tumor specificities and reference levels. Bjerner J; Norum LF; Nilsson O; Nustad K Tumour Biol; 2002; 23(6):315-23. PubMed ID: 12677089 [TBL] [Abstract][Full Text] [Related]
4. Detection of circulating anti-mucin 1 (MUC1) antibodies in breast tumor patients by indirect enzyme-linked immunosorbent assay using a recombinant MUC1 protein containing six tandem repeats and expressed in Escherichia coli. Tang Y; Wang L; Zhang P; Wei H; Gao R; Liu X; Yu Y; Wang L Clin Vaccine Immunol; 2010 Dec; 17(12):1903-8. PubMed ID: 20876819 [TBL] [Abstract][Full Text] [Related]
5. Breast cancer humoral immune response: involvement of Lewis y through the detection of circulating immune complexes and association with Mucin 1 (MUC1). Isla Larrain M; Demichelis S; Crespo M; Lacunza E; Barbera A; Cretón A; Terrier F; Segal-Eiras A; Croce MV J Exp Clin Cancer Res; 2009 Aug; 28(1):121. PubMed ID: 19715603 [TBL] [Abstract][Full Text] [Related]
6. Tissue and serum MUC1 mucin detection in breast cancer patients. Croce MV; Isla-Larrain MT; Demichelis SO; Gori JR; Price MR; Segal-Eiras A Breast Cancer Res Treat; 2003 Oct; 81(3):195-207. PubMed ID: 14620915 [TBL] [Abstract][Full Text] [Related]
7. Circulating anti-MUC1 IgG antibodies as a favorable prognostic factor for pancreatic cancer. Hamanaka Y; Suehiro Y; Fukui M; Shikichi K; Imai K; Hinoda Y Int J Cancer; 2003 Jan; 103(1):97-100. PubMed ID: 12455059 [TBL] [Abstract][Full Text] [Related]
8. MUC1 expression and anti-MUC1 serum immune response in head and neck squamous cell carcinoma (HNSCC): a multivariate analysis. Rabassa ME; Croce MV; Pereyra A; Segal-Eiras A BMC Cancer; 2006 Oct; 6():253. PubMed ID: 17064405 [TBL] [Abstract][Full Text] [Related]
9. Antigenic differences between metastatic cells in bone marrow and primary tumours and the anti-MUC1 humoral immune response induced in breast cancer patients. Croce MV; Isla-Larrain M; Tur R; Rabassa ME; Segal-Eiras A Clin Exp Metastasis; 2004; 21(2):139-47. PubMed ID: 15168731 [TBL] [Abstract][Full Text] [Related]
10. Humoral immune response against tumoral mucin 1 (MUC1) in breast cancer patients. Isla Larrain MT; Colussi AG; Demichelis SO; Barbera A; Cretón A; Segal-Eiras A; Croce MV Int J Biol Markers; 2013 Sep; 28(3):318-25. PubMed ID: 23828406 [TBL] [Abstract][Full Text] [Related]
11. Use of CA15‑3 for screening breast cancer: An antibody‑lectin sandwich assay for detecting glycosylation of CA15‑3 in sera. Choi JW; Moon BI; Lee JW; Kim HJ; Jin Y; Kim HJ Oncol Rep; 2018 Jul; 40(1):145-154. PubMed ID: 29749490 [TBL] [Abstract][Full Text] [Related]
12. An enzyme-linked immunosorbent assay for the measurement of circulating antibodies to polymorphic epithelial mucin (MUC1). von Mensdorff-Pouilly S; Gourevitch MM; Kenemans P; Verstraeten AA; van Kamp GJ; Kok A; van Uffelen K; Snijdewint FG; Paul MA; Meijer S; Hilgers J Tumour Biol; 1998; 19(3):186-95. PubMed ID: 9591045 [TBL] [Abstract][Full Text] [Related]
13. Detection of circulating anti-MUC1 mucin core protein antibodies in patients with colorectal cancer. Nakamura H; Hinoda Y; Nakagawa N; Makiguchi Y; Itoh F; Endo T; Imai K J Gastroenterol; 1998 Jun; 33(3):354-61. PubMed ID: 9658314 [TBL] [Abstract][Full Text] [Related]
14. Usefulness of Salivary and Serum Auto-antibodies Against Tumor Biomarkers HER2 and MUC1 in Breast Cancer Screening. Laidi F; Bouziane A; Errachid A; Zaoui F Asian Pac J Cancer Prev; 2016; 17(1):335-9. PubMed ID: 26838233 [TBL] [Abstract][Full Text] [Related]
15. Antibodies reactive with the protein core of MUC1 mucin are present in ovarian cancer patients and healthy women. Richards ER; Devine PL; Quin RJ; Fontenot JD; Ward BG; McGuckin MA Cancer Immunol Immunother; 1998 Jul; 46(5):245-52. PubMed ID: 9690452 [TBL] [Abstract][Full Text] [Related]
16. Humoral immune responses to MUC1 in women with a BRCA1 or BRCA2 mutation. Hermsen BB; Verheijen RH; Menko FH; Gille JJ; van Uffelen K; Blankenstein MA; Meijer S; van Diest PJ; Kenemans P; von Mensdorff-Pouilly S Eur J Cancer; 2007 Jul; 43(10):1556-63. PubMed ID: 17532207 [TBL] [Abstract][Full Text] [Related]
17. Humoral immune response to MUC1 and to the Thomsen-Friedenreich (TF) glycotope in patients with gastric cancer: relation to survival. Kurtenkov O; Klaamas K; Mensdorff-Pouilly S; Miljukhina L; Shljapnikova L; Chuzmarov V Acta Oncol; 2007; 46(3):316-23. PubMed ID: 17450466 [TBL] [Abstract][Full Text] [Related]
18. [Diagnostic value of combined detection of TPS, CA153 and CEA in breast cancer]. Zheng H; Luo RC Di Yi Jun Yi Da Xue Xue Bao; 2005 Oct; 25(10):1293-4, 1298. PubMed ID: 16234113 [TBL] [Abstract][Full Text] [Related]
19. Combination Twist1 and CA15-3 in axillary lymph nodes for breast cancer prognosis. Jiang X; Guo D; Li W; Yu T; Zhou J; Gong J Mol Med Rep; 2017 Mar; 15(3):1123-1134. PubMed ID: 28112378 [TBL] [Abstract][Full Text] [Related]
20. Soluble MUC1 and serum MUC1-specific antibodies are potential prognostic biomarkers for platinum-resistant ovarian cancer. Budiu RA; Mantia-Smaldone G; Elishaev E; Chu T; Thaller J; McCabe K; Lenzner D; Edwards RP; Vlad AM Cancer Immunol Immunother; 2011 Jul; 60(7):975-84. PubMed ID: 21461842 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]